Next Article in Journal
Bovine Vaccinia: Insights into the Disease in Cattle
Previous Article in Journal
Natural Variation in Resistance to Virus Infection in Dipteran Insects
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Viruses 2018, 10(3), 119; https://doi.org/10.3390/v10030119

Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo

1
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China
2
SIMOPRO, CEA, Université Paris-Saclay, F-91191 Gif Sur Yvette, France
3
Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China
*
Authors to whom correspondence should be addressed.
Received: 27 January 2018 / Revised: 8 March 2018 / Accepted: 8 March 2018 / Published: 9 March 2018
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [5501 KB, uploaded 12 March 2018]   |  

Abstract

Herpes simplex virus type 2 (HSV-2) is the causative pathogen of genital herpes and is closely associated with the occurrence of cervical cancer and human immunodeficiency virus (HIV) infection. The absence of an effective vaccine and the emergence of drug resistance to commonly used nucleoside analogs emphasize the urgent need for alternative antivirals against HSV-2. Recently, ABMA [1-adamantyl (5-bromo-2-methoxybenzyl) amine] has been demonstrated to be an inhibitor of several pathogens exploiting host-vesicle transport, which also participates in the HSV-2 lifecycle. Here, we showed that ABMA inhibited HSV-2-induced cytopathic effects and plaque formation with 50% effective concentrations of 1.66 and 1.08 μM, respectively. We also preliminarily demonstrated in a time of compound addition assay that ABMA exerted a dual antiviral mechanism by impairing virus entry, as well as the late stages of the HSV-2 lifecycle. Furthermore, in vivo studies showed that ABMA protected BALB/c mice from intravaginal HSV-2 challenge with an improved survival rate of 50% at 5 mg/kg (8.33% for the untreated virus infected control). Consequently, our study has identified ABMA as an effective inhibitor of HSV-2, both in vitro and in vivo, for the first time and presents an alternative to nucleoside analogs for HSV-2 infection treatment. View Full-Text
Keywords: herpes simplex virus type 2; ABMA; antiviral effect; entry; late stage; vesicle transport herpes simplex virus type 2; ABMA; antiviral effect; entry; late stage; vesicle transport
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Dai, W.; Wu, Y.; Bi, J.; Wang, S.; Li, F.; Kong, W.; Barbier, J.; Cintrat, J.-C.; Gao, F.; Gillet, D.; Su, W.; Jiang, C. Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo. Viruses 2018, 10, 119.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top